Eupnoos

Eupnoos is a UK-based digital diagnostics company pioneering non-invasive acoustic biomarkers for the early detection of cardio-pulmonary toxicity, particularly in patients receiving high-risk oncology therapies such as ADCs, TKIs, ICIs and CAR-T. Our platform uses a 45-second breath test captured via smartphone or handheld microphone to identify early physiological changes—congestion, restriction, obstruction and interstitial injury—often missed until severe by standard tools like CT, echocardiography or blood biomarkers.

Designed to operate at scale in both clinical trials and real-world care, Eupnoos supports continuous safety monitoring, regulatory compliance and earlier intervention, helping protect patients while reducing costly treatment delays and adverse-event-related system burden. We work with leading hospitals, pharma and CRO partners to validate, integrate and deploy this new generation of cardio-pulmonary safety technology.